FindTrial
Sign In

A clinical study of CapeOX+Cetuximab as first line therapy in patents with KRAS/BRAF wild type metastatic colorectal cancer (A pooled analysis of FLEET and FLEET2 study)

A clinical study of CapeOX+Cetuximab as first line therapy in patents with KRAS/BRAF wild type metastatic colorectal cancer (A pooled analysis of FLEET and FLEET2 study) - A pooled analysis of FLEET and FLEET2 study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000031233
Enrollment
65
Registered
2018-03-01
Start date
2018-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

None listed

Sponsors

The nonprofit organization Epidemiological & Clinical Research Organization.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients treated by CapeOx+Cetuximab in FLEET and FLEET2 study

Exclusion criteria

Exclusion criteria: nane

Design outcomes

Primary

MeasureTime frame
Response rate—

Secondary

MeasureTime frame
Progression free survival—

Countries

Japan

Contacts

Public Contactshigeyoshiiwamoto

Aichi medical University Cancer center

iwamoto.shigeyoshi.168@mail.aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026